Advancing pregnancy induces obvious physical changes for women over time.
Myopic traction maculopa (MTM) and macular hole retinal detachments (MHRDs) are complex scenarios that demand accurate diagnoses and high surgical expertise.
What's in a name? When it comes to ophthalmology, a lot. Persistent hyperplastic primary vitreous—an old name that addressees only the status of the primary vitreous—needs updating, said Michael Trese, MD.
First-line treatment for diabetic macular edema (DME) is overwhelmingly anti-vascular endothelial growth factor (VEGF) drugs, with more than two-thirds of clinicians around the world prescribing them for this patient population.
Retinal vein occlusions (RVOs) are a frequent cause of retinal vascular disease in patients older than 50 years.
With advances in local treatment of uveitis over the past decade, the therapeutic armamentarium has increased from depot injections with short-lasting activity to long-term treatments, said Thomas A. Albini, MD.
In patients with age-related macular degeneration managed by a treat-and-extend regimen, the visual acuity generally was maintained; lesion reactivation occurred frequently at about eight weeks; and longer induction phases between treatments was associated with worse outcomes.
Quantitative assessment of retinovascular features on ultra-widefield angiography images showed significant improvements in leakage and ischemia following treatment with aflibercept in patients with diabetic macular edema and retinal vein occlusion.
The metastatic prognosis does not increase when vitrectomy is performed at the time of brachytherapy.
The fluocinolone acetonide 0.2 mcg/day implant (Iluvien, Alimera Sciences) offers an additional option for treating diabetic macular edema that reduces the need for subsequent therapy with anti-vascular endothelial growth factor or steroid treatment.